This week, the European Commission proposed a “recalibration” of Supplementary Protection Certificates (SPCs) to boost investment in the development and manufacture of biosimilars and generics.
This week, the European Commission (EC) proposed a “recalibration” of Supplementary Protection Certificates (SPCs) to boost investment in the development and manufacture of biosimilars and generics.
An SPC is an intellectual property right that grants an extension of up to 5 years on a 20-year patent term for an innovative pharmaceutical. The goal of the SPC is to offset the loss of patent protection that occurs during the development and clinical trials of a generic or biosimilar. When it was first implemented, the SPC system sought to provide the pharmaceutical industry with sufficient incentives to develop innovative products within the European Union, and to prevent companies from relocating to other countries.
The new proposal seeks to amend the European Union’s legislation on SPCs to introduce a manufacturing exemption for export purposes during the term of an SPC. The exemption would restrict the protection conferred by the SPC in order to remove competitive disadvantages to EU-based generics and biosimilars manufacturers, namely by allowing a drug maker to manufacture a product in an EU member state for the sole purpose of exporting the product to a non-EU market (ie, a market that is not subject to an SPC).
According to the proposal, when in 2017, the EC launched a public consultation on SPCs, comments demonstrated broad support for the proposed waiver; while the SPC initially sought to spur innovation, the EC’s proposal notes that biosimilar and generic products will represent 80% of all medicines worldwide by volume in the year 2020, and SPCs keep EU-based manufacturers from producing any generics or biosimilars for a covered drug—even if the manufacture is exclusively for export to another market—during the protection period. “This problem puts EU-based industry at a disadvantage,” says the proposal, because manufacturers in non-EU countries do not fact the same restrictions.
Under the proposal, once an SPC has expired, biosimilar and generics companies who have established manufacturing lines for their export products will be able to use the same lines to manufacture products to supply the EU marketplace, an approach that the EC says will strengthen the EU supply chain.
The proposal notes that SPC protections will be left intact in the European Union, and that the EC will undertake a series of safeguards to ensure that products intended for export are not diverted to the EU market.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.